NASDAQ: ADPT

Adaptive Biotechnologies (ADPT) Stock Analysis & Forecast

Nov 13 close

$29.04−0.44 (−1.5%)

Gekko Brief

AI summaryNov 9 close

Adaptive Biotechnologies touched a 52-week high of $30.74 this week after third-quarter results showed revenue rising 39% year-over-year to $83.9 million, topping consensus of $71.57 million, with EPS of $0.020 against a projected $-0.093. Core Minimal Residual Disease revenue grew 44%, though some coverage noted a year-over-year sales slip to $83.9 million from $93.97 million and a larger net loss despite higher nine-month revenue. Separately, President and COO Julie Rubinstein sold approximately $954,441 of common stock between November 4 and November 6 following an options exercise under a Rule 10b5-1 plan, and eight research firms maintain a consensus "Moderate Buy" rating with an average target price near $30.06.

The stock closed at $30.26, up 8.1%, sitting above both its 50-day ($26.52) and 200-day ($19.87) moving averages, with one-month gains of 14.2% and six-month gains of 123.5%. The GekkoIndex reads 47.8, placing it in the Neutral zone, down 12.1 points over five days. Price sits 8.3% above Gekko Fair Value of $27.94.

The next earnings date is 4 February 2027, 86 days out, beyond a typical 20-day holding window, with Adaptive having beaten estimates in 7 of the last 8 quarters and an average post-earnings move of 7.6%. No insider, Congress, or unusual options activity appears in the respective 90-day and 30-day windows. Seasonality over the next 20 trading days has averaged -3.7% across 5 years, rising in 3 of them, a pattern worth noting given the stock's recent sharp run higher.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Adaptive Biotechnologies price vs fair value

$29.17$29.04Nov ’25May ’26Nov ’26
Close $29.04200-day averageGekko Fair Value $29.17

Adaptive Biotechnologies quick facts

Market cap
$4.70B
P/E ratio
—
Forward P/E
—
EPS, TTM
−$0.45
Revenue, TTM
$298.0M
Profit margin
-23.7%
Dividend yield
—
Beta
2.15
Volume
2.06M avg 2.19M
1-year return
+100.3%
Typical daily move
±6.6%
Typical 20-day move
±13.1%
50-day average
$26.91
200-day average
$20.09
Next earnings
Feb 4 after close
Shares outstanding
161.9M
52-week range
$12.00$32.21

Adaptive Biotechnologies swing-trade checklist

Adaptive Biotechnologies scores 3 supportive, 2 mixed and 0 headwinds across the 5 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed0 headwinds

  • Trendsupportive

    Above 50 and 200-day

    Close $29.04 is above the 50-day ($26.91) and 200-day ($20.09) averages, and the 50-day is above the 200-day.

    See the chart
  • GekkoIndexmixed

    52.5, Neutral

    Reading 52.5 is in the Neutral zone.

    See the GekkoIndex
  • Fair valuemixed

    0.4% below

    Price is within 5% of Gekko Fair Value (0.4% below).

    See fair value
  • Smart moneyno data

    No data

    No insider, Congress or unusual options activity in the window.

    See smart money
  • Earnings risksupportive

    Reports in 81 days

    Next report Feb 4, 2027, 81 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +4.5% on average

    From this point in the calendar, the next 20 trading days averaged +4.5% over 5 years, rising in 4 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Adaptive Biotechnologies stock chart and price history

Adaptive Biotechnologies closed at $29.04 on Nov 13, 2026, +100.3% over the past year, inside a 52-week range of $12.00 to $32.21.

Close50-day average200-day averageVolume
Adaptive Biotechnologies share price, past year, with 50-day and 200-day moving averages and volume$10$15$20$25DecJan 2026FebMarAprMayJunJulAugSepOctNov29.04

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+13.5%
3 months
+17.2%
6 months
+126.3%
1 year
+100.3%
The full ADPT chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ADPT in Gekko

Follow Adaptive Biotechnologies through every session

Put ADPT on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ADPT in GekkoFree for 7 days. No credit card required.

About Adaptive Biotechnologies

Adaptive Biotechnologies works on reading the immune system to help diagnose and treat disease. Its tools translate immune cell data into usable medical information, with clonoSEQ used clinically to detect and track minimal residual disease in blood cancers such as multiple myeloma and certain leukemias, and immunoSEQ supporting research into prognostic and diagnostic markers. The company also produced T-Detect COVID, a test for identifying past coronavirus infection, and immunoSEQ T-MAP COVID, which measures T-cell responses to vaccination.

The company serves life science researchers, clinical labs, and drug developers, and it continues building out additional products aimed at cancer, autoimmune conditions, and infectious disease. Alongside its existing offerings, it works with outside partners on new applications of its platform: Genentech on T-cell therapies targeting cancer-specific antigens, and Microsoft on blood-based diagnostics meant to catch multiple diseases early.

Adaptive Biotechnologies was started in 2009 and is based in Seattle, Washington, having originally operated under the name Adaptive TCR Corporation before adopting its current name in 2011. Its shares trade on the NASDAQ under the ticker ADPT.

Listed
NASDAQ
Sector
Health technology
Industry
Biotechnology
Website
adaptivebiotech.com

Adaptive Biotechnologies GekkoIndex: the smart money zone

Adaptive Biotechnologies’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 52.5, in the Neutral zone, down 0.2 points over five sessions.

010052.5Neutral

Down 0.2 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying157−0.1%−0.1%−0.1%−2.8%
Accumulation388+1.4%+2.4%+2.2%+1.6%
Neutral (current zone)649+0.3%+0.4%+1.5%+5.5%
Distribution93−2.6%−3.1%−3.1%+6.4%
Selling4Too few readings yet

Average ADPT share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the ADPT price, zone by zone.Track ADPT in Gekko

Is Adaptive Biotechnologies stock overvalued? Gekko Fair Value

Adaptive Biotechnologies trades 0.4% below Gekko Fair Value of $29.17, so the shares are about fair value on Gekko’s estimate.

Gekko’s own estimate of what Adaptive Biotechnologies shares are worth, recalculated every trading day.

$29.17

Gekko Fair Value, Nov 14, 2026

0.4% below fair value · About fair value

At the end of Aug 2026 the price was 17.9% below the estimate.

Gekko Fair ValueShare price, month end
$29$29Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ADPT in Gekko

Adaptive Biotechnologies insider and Congress trading

No open-market insider purchases were filed for Adaptive Biotechnologies, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

No open-market insider purchases were filed for ADPT in the last 90 days.

From Form 4 filings, dated to when each was filed.

Every ADPT insider filing, plotted on the chart in Gekko.Open ADPT in Gekko

Congress trades last 90 days

No trades in ADPT were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for ADPT, plotted on the chart in Gekko.Open ADPT in Gekko

Buybacks

Adaptive Biotechnologies has been buying back its own shares.

Latest authorization
$25.00M, Jun 15, 2026
Bought back, quarter ended Jun 30, 2026
$25.00M
As a share of market cap
0.53%

From company filings.

Adaptive Biotechnologies earnings: next date and track record

Adaptive Biotechnologies reports on Feb 4, 2027, after the close (81 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±7.6%average move across the report
4 of 8reports followed by a gain

Share-price move across each report

+1.2%Nov ’24+9.2%Feb ’25−10.5%May ’25+7.1%Aug ’25−15.9%Nov ’25−8.8%Feb ’26−0.5%May ’26+7.4%Jul ’26
ReportedEPSSurpriseRevenueSurpriseMove
Jul 29, 2026−$0.25
est −$0.13
−87.1%$71.55M
est $65.44M
+9.3%+7.4%
May 5, 2026−$0.13
est −$0.16
+18.8%$70.90M
est $61.03M
+16.2%−0.5%
Feb 5, 2026−$0.09
est −$0.19
+52.6%$71.68M
est $60.89M
+17.7%−8.8%
Nov 6, 2025$0.06
est −$0.18
+133.3%$93.97M
est $64.63M
+45.4%−15.9%
Aug 5, 2025−$0.17
est −$0.24
+29.2%$58.88M
est $55.40M
+6.3%+7.1%
May 5, 2025−$0.20
est −$0.34
+41.2%$52.44M
est $42.68M
+22.9%−10.5%
Feb 12, 2025−$0.23
est −$0.27
+14.8%$47.46M
est $46.05M
+3.1%+9.2%
Nov 7, 2024−$0.22
est −$0.27
+18.5%$46.44M
est $40.21M
+15.5%+1.2%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Adaptive Biotechnologies stock forecast and analyst price targets

Analysts’ average 12-month price target for Adaptive Biotechnologies is $32.57, +12.2% from the last close, from 8 firms rating the stock in the last 90 days.

$32.57consensus 12-month target, +12.2% from the last close
Low $27High $35
Buy7
Hold1
Sell0

Each firm’s latest rating in the last 90 days: 8 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 10Piper SandlerBuy, reiterated$35+20.5%
Nov 10GuggenheimBuy, reiterated$34+17.1%
Nov 9J.P. MorganBuy, reiterated$35+20.5%
Nov 5TD CowenBuy, reiterated$34+17.1%
Nov 5Piper SandlerBuy, maintained$27.50−5.3%
+1.5%average 20-day move after past Neutral readings
+4.5%average move over the next 20 trading days in the last 5 years
±6.6%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Adaptive Biotechnologies seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Adaptive Biotechnologies averaged +4.5% across the last 5 years, rising in 4 of them.

Next 20 trading days, by year

−18.4%2021+3.1%2022+21.3%2023+12.9%2024+11.3%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−2.2%2 of 5
Next 10 trading days+3.5%2 of 5
Next 15 trading days0.0%3 of 5
Next 20 trading days+4.5%4 of 5
Next 30 trading days+3.3%3 of 5

For scale, ADPT’s typical 20-trading-day move in either direction is about 13.1%.

Adaptive Biotechnologies market cap and key statistics

Adaptive Biotechnologies’s market cap is $4.70B and revenue of $298.0M over the last twelve months.

Valuation

Market cap
$4.70B
EPS, TTM
−$0.45
Gekko Fair Value
$29.17

Trading

Volume
2.06M
Avg volume, 20 days
2.19M
52-week high
$32.21
52-week low
$12.00
Shares outstanding
161.9M

Financials

Revenue, TTM
$298.0M
Profit margin
-23.7%
Return on equity
-36.4%
Quarterly earnings growth, YoY
−70.1%

Risk and income

Beta
2.15
Typical daily move
±6.6%
Typical 20-day move
±13.1%

Adaptive Biotechnologies peers

Adaptive Biotechnologies’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Adaptive Biotechnologies stock FAQ

What is Adaptive Biotechnologies’s market cap?

Adaptive Biotechnologies’s market cap is $4.70B at the Nov 13, 2026 close of $29.04, with 161.9M shares outstanding.

What is the Adaptive Biotechnologies stock forecast?

The consensus analyst 12-month price target for Adaptive Biotechnologies is $32.57, +12.2% from the last close. Of the 8 firms that rated the stock in the last 90 days, 7 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Adaptive Biotechnologies stock overvalued or undervalued?

On Gekko’s estimate Adaptive Biotechnologies is about fair value: the Nov 13, 2026 close of $29.04 is 0.4% below Gekko Fair Value of $29.17. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Adaptive Biotechnologies report earnings next?

Adaptive Biotechnologies is expected to report on Feb 4, 2027, after the market closes (81 days away). Analysts expect earnings of −$0.04 per share on revenue of $80.62M. Adaptive Biotechnologies beat the earnings estimate in 7 of its last 8 reports, moving 7.6% on average across the report.

What is Adaptive Biotechnologies’s 52-week high and low?

Adaptive Biotechnologies’s 52-week high is $32.21 and its 52-week low is $12.00; it closed at $29.04 on Nov 13, 2026, +100.3% over the past year. Over the last five years the shares peaked at $33.82 on Nov 15, 2021.

Is Adaptive Biotechnologies stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 5 items with data read as supportive (trend, earnings risk and seasonality), 2 as mixed (gekkoindex and fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Adaptive Biotechnologies the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.